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Ichthyotherapy as Alternative Treatment for Patients with
Psoriasis: A Pilot Study
Martin Grassberger and W. Hoch
Medical University of Vienna, Sensengasse 2, A-1090 Vienna, Austria
Ichthyotherapy (therapy with the so-called ‘Doctorfish of Kangal’, Garra rufa) has been shown to be
effective in patients with psoriasis in the Kangal hot springs in Turkey. This study evaluates the efficacy
and safety of ichthyotherapy in combination with short-term ultraviolet A sunbed radiation in the
treatment of psoriasis under controlled conditions. We retrospectively analyzed 67 patients diagnosed
with psoriasis who underwent 3 weeks of ichthyotherapy at an outpatient treatment facility in Lower
Austria between 2002 and 2004. Main outcome measures are as follows: overall relative reduction in
Psoriasis Area Severity Index (PASI) score; proportion of patients with an improvement in their PASI
score of  75% (PASI-75) and  50% (PASI-50); patient-reported outcomes assessed with a custom
questionnaire; and patient follow-up with a questionnaire sent out in March 2005. Safety was evaluated
by reviewing adverse events and vital signs. Overall there was a 71.7% reduction in PASI score
compared to baseline (P < 0.0001). Of the 67 patients studied, 31 (46.3%) achieved PASI-75 and 61
patients (91%) achieved at least PASI-50. Patients reported substantial satisfaction with the treatment.
The reportedmean remission period was 8.58 months [95% confidence interval (CI) 6.05–11.11]. A total
of 87.5% of patients reported a more favorable outcome with ichthyotherapy, when asked to compare
ichthyotherapy to other previously tried therapies. Sixty-five percent stated that after the relapse their
symptoms were less severe than before treatment. There were no significant adverse events. The benefit
demonstrated in this study along with the favorable safety profile suggests that ichthyotherapy could
provide a viable treatment option for patients with psoriasis.
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Introduction
Psoriasis is a common skin disorder with a worldwide
distribution; the average prevalence in Europe and the USA
has been estimated at 2% (1). Whilst considerable advances
have been made in the management of this disease in recent
years, there is no cure, and no simple, safe and invariably
effective treatment (2). The disease carries a substantial
burden even when not extensive, and is associated with
widespread treatment dissatisfaction (3). A wide range of
treatments is offered for psoriasis. Some patients rely on
conventional pharmacological methods; others try alternative
and complementary treatment modalities (4).
Surely one of the most unusual alternative treatments is the
so-called ‘Doctorfish of Kangal’ in the Central Anatolia region
of Turkey. This treatment was first mentioned in The Lancet in
1989 (5) but the details of the treatment were published only
recently by O ¨zcelik et al. (6) According to the authors two
different types of fish live in the pools of the Kangal hot
spring: Cyprinion macrostomus and Garra rufa. Both fish are
members of the carp and minnow family (Cyprinidae). Garra
rufa is regarded as the main therapeutic. Garra rufa is
normally a bottom dweller, where it adheres by suction to
rocks with its ventral crescent-shaped mouth to feed on phyto-
and zooplankton (7). However, in the hot pools of Kangal,
where phyto- and zooplankton are scarce, these fish feed on the
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psoriasis and atopic dermatitis (6).
Whether this remarkable treatment is also effective outside
of the Kangal hot spring in Turkey is unknown. Since there
have been many unscientific and misleading names for this
kind of therapy, we suggest the term ‘ichthyotherapy’, in
accordance with other so-called biotherapy concepts such as
maggot therapy (use of sterile fly larvae), hirudotherapy (use
of leeches) and apitherapy (use of bee venom). In this
retrospective study, we set out to evaluate the efficacy and
safety of ichthyotherapy when used in combination with
short-term ultraviolet (UV) A radiation in patients with
psoriasis vulgaris in an outpatient treatment facility.
Patients and Methods
Patients
We retrospectively analyzed 67 patients diagnosed with
psoriasis who underwent 3 weeks of ichthyotherapy combined
with a short course of UVA sunbed treatment at an outpatient
treatment facility in Lower Austria between 2002 and 2004.
All patients had moderate to severe chronic plaque psoriasis.
Patients referred themselves to the treatment facility to find
relief from their symptoms. The costs of this treatment were
not covered by the patients’ health care insurance. All patients
had signed informed consent and were under constant medical
supervision throughout the course of treatment.
Treatment Regimen
Treatment lasted 3 weeks. A daily 2 h ‘fish bath’ (Fig. 1) was
taken in a bathtub at a comfortably warm temperature
(36–37 C). Patients with no contraindication to UV exposure
(reported history of UV-related skin malignancies) used a
commercially available stand-up rapid-tan facility (Cyclone 60
with 60 Cosmolux VHR160 lamps, CMC Sun Capsule USA)
for 3–5 min after each bath session according to skin type. The
spectral emission of the lamps is shown in Fig. 2. After UV
exposure, the patients applied a generic skin lotion (Pharmacy
Neunkirchen, Austria) containing glycerine, Butyrospermum
parkii (Shea butter) and Aloe vera extract. If psoriasis lesions
severely involved the scalp, the patient’s head was shaved
before treatment.
Treatment Tubs
The treatment tubs, made from food-safe plastic (Chemo ,
Weinstadt, Germany) had a capacity of 1100 l, were filled to
 80% capacity. Between 250 and 400 fishes were used,
depending on the size and severity of the skin lesions. The
bathtubs were equipped with an elaborate fresh water system,
the technical details of which will be published elsewhere. The
water in the tubs was constantly filtered and sterilized
(700 liters per h) by a filter pump and a UVC water
sterilization device and was simultaneously enriched with
oxygen. The water was exchanged completely 3 to 4 times a
day. A thermostat was used to maintain a comfortable water
temperature between 36 and 37 C.
The fish, reared in an adjacent breeding facility, ranged from
5 to 10 cm in length ( 1.5 years old) when used for treatment.
In contrast to the Kangal hot spring, where they lack nutrients
owing to the high temperatures of the spring, the fish were fed
commercially available fish food (TetraMin , Tetra GmbH,
Melle, Germany) daily after the treatment sessions.
Water samples were tested monthly for Legionella species
and Pseudomonas aeruginosa. The fish were examined for
Aeromonas hydrophila, Aeromonas sobria, Aeromonas caviae,
Mycobacterium marinum and Mycobacterium piscium to rule
out any risk for potential zoonotic infections. Since the fishes
were given only commercially available fish food, the risk of
Figure 1. Patient sitting in standard treatment tub during therapy with the
Kangal fish G. rufa.
Figure 2. Spectral emission of employed UVA lamps.
484 Ichthyotherapy for psoriasisDiphyllobothrium latum (fish tapeworm) infestation could be
ruled out based on the absence of an intermediate host.
Each patient was allocated to a single bathing tub for the
duration of the 3 week treatment, and no two patients shared
the same tub at any time during that period. After the 3 week
treatment, each tub along with the technical equipment was
disinfected (2% solution Dodarcana  Rapid, Schu ¨lke & Mayr,
Austria) for 1 h.
Assessment
Clinical Assessment
The primary efficacy outcome measure was the overall total
reduction in Psoriasis Area Severity Index (PASI) score and
the proportion of patients with 50 and 75% improvement in
PASI score (PASI-50 and PASI-75) at week 3, relative to
baseline. The PASI is a physician-accessed score, recognized
by the US Food and Drug Administration to assess efficacy of
psoriasis therapies in clinical trials. The PASI score takes into
account the extent of involved skin surface and the severity of
erythema, desquamation, and plaque induration. The compos-
ite score range from 0 to 72, with higher numbers indicating
more severe disease and a reduction in score representing
improvement. The PASI-75 is the currently recognized bench-
mark of end points used in psoriasis clinical trials. PASI-50 is
also regarded as a clinically significant end point in the asses-
sment of psoriasis (8). PASI was assessed on high-resolution
digital color photographs taken at baseline and at the end of the
3 week treatment period. Baseline measurements were those
made closest but prior to the beginning of treatment.
Additionally, response to treatment was defined according to
the rate of improvement in PASI score, as follows: complete
response, >95% improvement; good or marked, 75–94%;
moderate, 50–74%; slight, 25–49%; and none, <25%.
Patient-reported Outcomes
Patient-reported outcomes were evaluated by a short custom
questionnaire immediately after the 3 week course of treatment
(Table 1) and by a follow-up questionnaire sent to all patients
after treatment in March 2005 to assess the duration of
remission, the number of different treatment regimens prior to
ichthyotherapy, the severity of a possible relapse and the
personal satisfaction with ichthyotherapy when compared with
previous treatments (Tables 2 and 3). At this point the time
elapsed since the end of therapy was from 3 months to almost
3 years.
Safety Evaluation
The safety and tolerability of the therapy were evaluated by
reviewing adverse events (assessed weekly), vital signs and a
weekly physical examination.
Table 1. Answers to the short custom questionnaire immediately after 3 weeks of therapy (n ¼ number of completed questions)
Extremely Considerable A little Not at all
How much did your skin condition improve after the treatment considering
Itching? (n ¼ 63) 46 (73.0%) 15 (23.8%) 2 (3.2%) 0
Pain? (n ¼ 54) 48 (88.9%) 6 (11.1) 0 0
Skin tension? (n ¼ 62) 51 (82.3%) 11 (17.7%) 0 0
Induration? (n ¼ 64) 49 (76.6%) 14 (21.9%) 1 (1.6%) 0
Scaling? (n ¼ 66) 56 (84.8%) 9 (13.6%) 1 (1.5%) 0
Psychological problems?* (n ¼ 66) 31 (47.0%) 18 (27.3%) 4 (6.1%) 1 (1.5%)
Have you attained your treatment goal? (n ¼ 66) 44 (66.7%) 21 (31.8%) 1 (1.5%) 0
Yes Probably yes Probably no No
Would you use this kind of therapy again? (n ¼ 66) 59 (89.4%) 6 (9.1%) 1 (1.5%) 0
*Twelve patients (18.2%) stated that they had no psychological problems prior to treatment.
Table 2. Patient-reported psoriasis treatmentsused prior to ichthyotherapy
as assessed by the mailed follow-up questionnaire
N %
Cortison 29 72.5
UVA/UVB 21 52.5
Vit. D3 19 47.5
Sole therapy 18 45
PUVA 17 42.5
Oilbath 16 40
Homeopathy 12 30
Dead Sea 9 22.5
Salicylic acid 9 22.5
Dithranol 9 22.5
Tar preparations 9 22.5
Fumaric acid 8 20
Acupuncture 7 17.5
Balneophototherapy 6 15
Vit. A 4 10
MTX 1 2.5
Cyclosporin 0 0
Other (including new biologicals) 11 27.5
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The primary end point (efficacy of treatment) was evaluated
by comparing the mean PASI score before and after 3 weeks of
treatment. The PASI scores were analyzed using a Wilcoxon’s
signed rank test for paired comparison. P-values   0.05 were
considered statistically significant. Analysis was carried out
using Prism 4 for Macintosh (GraphPad Software, Inc.,
San Diego, CA).
Results
Patients’ Characteristics
Sixty-seven patients, 39 male and 28 female, were included in
this retrospective study. All 67 patients completed the 3 week
treatment. Ages ranged between 10 and 75 years [mean
41.01 years, 95% confidence interval (CI) 37.51, 44.52].
The mean duration of psoriasis at baseline was 13.9 years
(range 1–35 years; 95% CI 11.6, 16.21).
Treatment Efficacy
Physician-assessed Outcomes
At the end of the 3 week treatment course, 31 of the 67 patients
(46.3%) achieved PASI-75 and 30 other patients (44.8%)
achieved PASI-50. The mean PASI score at baseline for the
entire study cohort was 18.9 ± 12.37 (95% CI 15.89, 21.9).
PASI score at the end of the treatment period was 5.34 (95% CI
4.27, 6.42). Overall there was a 71.7% reduction in PASI score
compared to baseline (P < 0.0001) (Fig. 3).
Response to treatment was complete in three patients
(4.5%), marked in 29 (43.3%), moderate in 29 (43.3%) and
slight in 6 (8.9%). No patient failed to respond at all.
Patient-reported Outcomes
In the short questionnaire given immediately after the 3 weeks
of treatment, patients reported substantial satisfaction with the
treatment (Table 1).
Of the 67 follow-up questionnaires sent to the patients in
March 2005, 64 were deliverable. Forty questionnaires were
returned, giving a response rate of 60%. The mean time since
the end of treatment was 21.8 (95% CI 18.99, 24.68). The
reported mean remission period was 8.58 months (range
1–30 months; 95% CI 6.05, 11.11) with two patients (5.1%)
still in remission at the time the questionnaire was received
(time elapsed since the end of therapy was 12 and 26 months,
respectively). The mean number of previously used other
therapies was 5 ± 3 (± SD) (range 0–12; 95% CI 4.02, 5.93)
(Table 2). When asked to compare their treatment results with
all previously used therapies, 87.5% of patients reported a
more favorable outcome with ichthyotherapy. A total of 65.1%
stated that after the relapse their symptoms were less severe
than compared with baseline (Table 3).
Safety Evaluation, Side effects
No severe side effects were recorded during the treatment
period. Mild, transient bleeding from open crusted lesions was
reported by one patient with eczema, and UV radiation-related
erythema by two others. No clinically significant pattern of
changes in vital signs were observed during the study period.
Ichthyotherapy in combination with UVA treatment was
generally very well tolerated.
Discussion
This retrospective study indicates that ichthyotherapy used in
combination with short-term UVA radiation is an effective and
safe treatment for psoriasis vulgaris. A total of 46.3% of the
67 patients achieved PASI-75 and an additional 44.8% patients
achieved at least PASI-50 after a 3 week course of treatment
with the ‘Doctorfish of Kangal’ G. rufa (Fig. 4). It is well
established that a 75% improvement in PASI score is a
clinically meaningful end point for clinical trials, and there is
strong evidence demonstrating that a 50% improvement in
PASI score is also associated with a significant improvement
in the patients quality of life (7). These findings are further
supported by the results of the questionnaire completed by the
patients immediately after treatment (Table 1).
Table 3. Results of the mailed follow-up questionnaire (n ¼ number of
completed questions)
More Equally Less
Compared to other tried
treatments this kind of
therapy helped me (n ¼ 40)
35 (87.5%) 4 (10%) 1 (2.5%)
If a relapse occurred, how severe
were the symptoms compared
to baseline?* (n ¼ 39)
3 (7.7%) 10 (25.6%) 24 (61.5%)
*Two patients (5.1%) still in remission at the time the questionnaire were
received.
Figure 3. Box plot of PASI scores before and after treatment. Horizontal lines
show 75th percentile, median and 25th percentile, whiskers indicate range.
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The results of the follow-up survey indicate that most of the
patients were more satisfied with ichthyotherapy than with any
other previously tried treatment. This satisfaction might be
explained, at least in part, by the rather long-reported mean
remission period of 8.6 months. The response rate of the
survey is comparable to those of other mail-based surveys (9).
However, we are aware that this approach leaves room for
potential non-response bias; patients with unfavorable results
(i.e. early relapse) may have been less likely than others to
respond to our survey.
Combination with UV Radiation
In this study it was also shown that ichthyotherapy combined
with UVA radiation was generally well tolerated with only
three patients experiencing mild side effects. Two of these
three patients showed UVA treatment-related erythema.
Whereas a prolonged UVA treatment course, or frequently
repeated courses, may have an, as yet, undefined risk with
regard to melanoma and aging changes, a recent study suggests
that UVB but not UVA radiation initiates melanoma (10).
However, we are aware of the risks as identified by the British
Photodermatology Group Workshop (11), and therefore
suggest to further evaluate ichthyotherapy in combination
with broadband UVB and narrowband UVB treatment.
Possible Mechanisms of Action
Several mechanisms have been suggested regarding the
observed efficacy of ichthyotherapy in Turkey (6). One
obvious mechanism is the physical contact with the fish,
which feed on the desquamating skin, thus leading to a rapid
reduction of the scales. This phenomenon was also consist-
ently observed in our patients, who reported a pleasing
micromassage like feeling while the fish nibbled at their
skin. The fish seem to prefer affected to healthy skin, possibly
it is easier to nibble at this surface. Another suggested
Figure 4. Three patients before and after a 3 week combined treatment with ichthyotherapy and UVA radiation.
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the high altitude (1650 m) of the Kangal spa (6). Phototherapy
is a well-recognized option for patients with widespread
psoriasis lesions with climatotherapy being the simplest form
(2). However, a simultaneous removal of scales by the fish
probably facilitates the penetration of UV rays to the dermis.
This exposure of the lesions may explain the better outcome of
combined ichthyotherapy/UVA treatment when compared
with the poor results of UVA sunbed treatment alone (12). A
third suggested mechanism of ichthyotherapy in Kangal is the
presence of a high level of selenium (1.3 mg l
 1) in the hot
spring water (6). While O ¨zcelik et al. (6) argue that selenium
constitutes an important factor to treatment success in Kangal,
an analysis of the water used in our study revealed a selenium
concentration of <5mgl
 1.Therefore, selenium is not likely to
have contributed to the observed efficacy of ichthyotherapy
reported in the present study. A fourth mechanism suggested
by O ¨zcelik et al. (6) is the reverse Koebner phenomenon. The
reverse Koebner phenomenon is seen when an area of psoriasis
clears following injury (13). However, it had been shown that
destruction of the dermal papillae within the injured tissue
plays the key role in preventing epidermal hyperplasia of
psoriasis (14). Therefore, it seems unlikely that the reverse
Koebner phenomenon contributes to the observed efficacy of
ichthyotherapy. Finally, psychological factors such as stress
are regarded a causal or exacerbating factor in psoriasis (1).
Thus, the 2 h daily fish bath, which most patients referred to as
relaxing and pleasing, might have contributed to the observed
treatment effect by reducing patients’ stress and enhancing
psychological well-being.
Treatment Protocol
There are two important key differences between this study
and the study by O ¨zcelik et al. (6) concerning treatment
protocol.First, in our studythe patients were requiredto stay in
the treatment tubs for only 2 h per day, whereas the mean stay
in the pools in Kangal was 7.4 ± 1.1 h a day (6). This shortened
treatment time makes ichthyotherapy more acceptable for the
patients and considerably improves compliance. Second, at the
treatment facility described herein, each patient was allocated
a personal bathing tub, and the fish only came into contact with
a single patient. Conversely, in the pools of the Kangal hot
spring patients are required to take their bath with 10–20
patients simultaneously (M.G., personal observation). This
approach might be unacceptable for some patients and a
possible hygienic risk cannot be entirely excluded. It is evident
that many questions remain unanswered concerning the
optimal protocols for ichthyotherapy. In the absence of studies
to address these issues, we recommend that the described
protocol may be used for guidance.
Conclusion
The present study is limited by the relatively small number of
patients treated and by lack of a control group. Randomized
studies would be needed to compare the ichthyotherapy
treatment with controls (e.g. water with the UV therapy alone)
and to assess treatment with standardized health-related
quality of life questionnaires.
In summary, the observed benefit, along with the favorable
safety profile, suggests that ichthyotherapy combined with a
short course UVA treatment could provide a viable treatment
option for patients with psoriasis vulgaris. Prospective
controlled studies are now warranted to validate the efficacy
of this unusual treatment modality.
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